Repurposing of existing antiviral drugs, immunological modulators, and
supportive therapies represents a promising path toward rapidly
developing new control strategies to mitigate the devastating public
health consequences of the COVID-19 pandemic. A comprehensive
text-mining and manual curation approach was used to comb and summarize
the most pertinent information from existing clinical trials. Drugs with
previous efficacy against related betacoronaviruses like SARS and MERS
were also systematically evaluated as potentially promising candidates
for drug repositioning.